Hypertrophy, Left Ventricular: Clinical Trials

18 trials for Hypertrophy, Left Ventricular, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 5 unknown, 2 terminated, 1 withdrawn. 18 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 318Completed 10, Unknown 5, Terminated 2, Withdrawn 1
Phase 24Unknown 2, Completed 1, Withdrawn 1

Follow Hypertrophy, Left Ventricular: new trials by email Literature Review of Hypertrophy, Left Ventricular trials Research Report on Hypertrophy, Left Ventricular

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
Valsartan, Placebo Oral Tablet - Aortic Valve Stenosis, Valsartan
Phase 2 / Phase 3WithdrawnUniversity Hospital, Limoges2023-01-022023-03-17
Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
SGLT2 inhibitor, Placebo - Aortic Stenosis, Left Ventricle Hypertrophied
Phase 2 / Phase 3UnknownUniversity of Aarhus1062022-02-122022-02-15
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low
Phase 2 / Phase 3UnknownUniversity Hospital Birmingham2202009-10-012011-08-11
Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis
ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy - Left Ventricular Hypertrophy, Hypertension
Phase 3CompletedMario Negri Institute for Pharmacological Research2692009-05-012021-01-11
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL - Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Phase 3TerminatedAbbott122009-01-012012-01-20
Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis
Atorvastatin 80 mg - Aortic Valve Stenosis, Ventricular Hypertrophy
Phase 3UnknownUniversity Hospital, Strasbourg, France602008-12-012015-06-19
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
spironolactone, placebo - Primary Hypertension
Phase 3CompletedUniversity of Erlangen-Nürnberg Medical School502008-03-012012-07-10
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy
Phase 3CompletedAbbVie (prior sponsor, Abbott)2272008-02-012013-03-12
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
Valsartan, Amlodipine, Hydrochlorothiazide - Hypertension; Hypertrophy, Left Ventricular
Phase 3CompletedNovartis902007-03-012011-05-11
Stenting of Renal Artery Stenosis in Coronary Artery Disease Study
stenting angioplasty plus medical therapy, Medical therapy - Renal Artery Stenosis, Left Ventricular Hypertrophy
Phase 3UnknownAzienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele1682006-04-012010-08-02
Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis
Candesartan - Aortic Valve Stenosis, Left Ventricular Hypertrophy
Phase 3UnknownOdense University Hospital1402006-02-012009-06-30
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
Diltiazem, Placebo - Hypertrophic Cardiomyopathy
Phase 2 / Phase 3CompletedBrigham and Women's Hospital392006-01-012015-04-07
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo - Hypertension, Left Ventricular Hypertrophy
Phase 3CompletedNovartis Pharmaceuticals4602005-10-012011-05-26
Hypertension in Hemodialysis Patients (Aim 3)
Lisinopril, Atenolol - Hemodialysis, Hypertension
Phase 3TerminatedIndiana University2002005-08-012016-01-18
The CLEVER Study - Coreg And Left Ventricular Mass Regression
carvedilol MR, atenolol, lisinopril - Hypertrophy, Left Ventricular
Phase 3CompletedGlaxoSmithKline2872005-01-012016-12-16
Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients
ACE Inhibition, Intensified Blood Pressure Control, Add-on Angiotensin Receptor Blockade - Children, Chronic Renal Failure
Phase 3CompletedHeidelberg University4001998-01-012010-01-12
A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.
epoetin alfa - Anemia, Kidney Failure
Phase 3CompletedJanssen-Ortho Inc., Canada1721997-12-012011-02-01
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years - Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Phase 3CompletedOrganon and Co4961995-06-012022-02-15

Narrower conditions

Hypertension (6)  ·  Aortic Valve Stenosis (5)  ·  Renal Insufficiency, Chronic (2)  ·  Anemia (1)  ·  Atrial Fibrillation (1)  ·  Cardiac Output, Low (1)  ·  Cardiomyopathy, Hypertrophic (1)  ·  Cardiovascular Diseases (1)  ·  Disease Progression (1)  ·  Essential Hypertension (1)  ·  Hypertrophy (1)  ·  Kidney Failure, Chronic (1)  ·  Myocardial Reperfusion Injury (1)  ·  Overweight (1)

Broader conditions

Cardiomegaly (18)  ·  Heart Diseases (18)  ·  Pathological Conditions, Anatomical (18)  ·  Pathological Conditions, Signs and Symptoms (18)  ·  Cardiovascular Diseases (17)  ·  Hypertrophy (17)  ·  Vascular Diseases (9)  ·  Aortic Valve Disease (6)  ·  Heart Valve Diseases (6)  ·  Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Kidney Diseases (5)  ·  Male Urogenital Diseases (5)  ·  Pathologic Processes (5)  ·  Urogenital Diseases (5)

Interventions

Atenolol (2)  ·  Lisinopril (2)  ·  Losartan (2)  ·  Valsartan (2)  ·  paricalcitol (2)  ·  Amlodipine (1)  ·  Atorvastatin (1)  ·  Diltiazem (1)  ·  Duration of Therapy (1)  ·  Epoetin Alfa (1)  ·  Hydrochlorothiazide (1)  ·  Nutrition Therapy (1)  ·  Perhexiline (1)  ·  Ramipril (1)  ·  Sodium-Glucose Transporter 2 Inhibitors (1)

Sponsors

AbbVie (prior sponsor, Abbott) (1)  ·  Abbott (1)  ·  Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele (1)  ·  Brigham and Women's Hospital (1)  ·  GlaxoSmithKline (1)  ·  Heidelberg University (1)  ·  Indiana University (1)  ·  Janssen-Ortho Inc., Canada (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Novartis (1)  ·  Novartis Pharmaceuticals (1)  ·  Odense University Hospital (1)  ·  Organon and Co (1)  ·  University Hospital Birmingham (1)  ·  University Hospital, Limoges (1)

Countries

Germany (6)  ·  Italy (6)  ·  United States (6)  ·  Czechia (3)  ·  France (3)  ·  Poland (3)  ·  Russia (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Denmark (2)  ·  Puerto Rico (2)  ·  Romania (2)  ·  Sweden (2)  ·  Taiwan (2)

Top investigators

Ann Eldred, MD (1)  ·  Carmelita Marcantoni, M.D. (1)  ·  Carolyn Y Ho, MD (1)  ·  Dennis Andress, MD (1)  ·  Domeinco Pagano, MD FRCS (1)  ·  Franz Schaefer, MD (1)  ·  Henrik Nissen, MD, PhD (1)  ·  Jacob E Moller, Md, Ph.D (1)  ·  Jordi S Dahl, MD, MMSci (1)  ·  Lars I Andersen, MD, DMSc (1)

Results publications

PMID 18591942, PMID 14630977, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 16253719, PMID 19332468, PMID 20001655, PMID 20589977, PMID 20601389, PMID 21239405, PMID 21242674, PMID 21304095, PMID 21353251, PMID 21358415, PMID 21720264, PMID 21746765, PMID 22243363, PMID 22337679, PMID 22495466, PMID 22695506, PMID 22753219, PMID 22869821, PMID 23194491, PMID 23316326, PMID 23403268, PMID 24173271, PMID 24379001, PMID 24398888, PMID 24723582, PMID 25340854, PMID 26056336, PMID 26089332, PMID 26378687, PMID 27085434, PMID 27536421, PMID 27590665, PMID 29151037, PMID 29176391, PMID 29474712, PMID 29580174, PMID 30676480, PMID 32586143, PMID 32586346, PMID 33782036, PMID 35213289, PMID 35224730, PMID 35345262

NIH funding

2008 (1), K23HL078901 (1), R01DK062030 (1)